We advised BOM Capital with its investment in Gilde Healthcare IV, an investment fund investing in innovative medical technology companies, digital health and therapeutics in Europe and the US.

We advised LSP (Life Sciences Partners) with its investment in the Series B financing round of ViCentra, a company developing and commercializing an insulin pump system for diabetes patients.  With its Kaleido insulin pump, ViCentra aims to reduce the impact that diabetes can have on daily life. The syndicate, led by LSP with participation from existing investor INKEF, will invest EUR 10 million. The funding will support European commercialization of the Kaleido system and preparations for US market entry.

We advised BOM Capital with its investment in Endeit Fund II, an investment fund providing growth equity to European internet technology companies.

We advised Stichting DOEN with its investment in Zeewaar, a company that farms seaweed and produces and sells seaweed products.

We advised BOM Capital on the sale of its shares in Acerta Pharma to Astra Zeneca. BOM Capital was one of the early investors in Acerta Pharma. Astra Zeneca has taken a 55% stake in Acerta Pharma and an option to acquire the remaining 45% interest. This sale is after BioNovion the second successful exit in biotech for BOM Capital in 2015, is the largest in the history of BOM Capital and the largest biotech deal so far in the Netherlands.

We advised BOM Capital with its investment in Aglaia Oncology Fund II, an investment fund focusing on biomedical companies in the field of oncology.

We advised Stichting DOEN with its investment in Nederland Isoleert, a company that provides isolation for homes in the Netherlands by way of collective purchasing.

We advised Stichting DOEN with its investment in Chocolatemakers, manufacturers of sustainable chocolate located in Amsterdam.

Gimv acquired the Dutch company Brakel together with the existing management team. The transaction was partly financed through a leveraged finance facility with related security in the Netherlands, U.K. and Belgium. Rabobank acted as lender in the acquisition financing. Brakel is an important player in the field of glass daylight constructions as well as ventilation and fire safety solutions. ^*

^*  Marcel van de Vorst led this transaction for Gimv whilst at previous law firm.

We advised BOM Capital on the sale of its shares in BioNovion to Aduro Biotech. The company, based on the Pivot Park in Oss, is the new European headquarters of Nasdaq-listed Aduro Biotech and renamed in Aduro Biotech Europe. Aduro acquired BioNovion to broaden its technological portfolio and to increase the potential of immunotherapy. BioNovion develops monoclonal antibody therapies against cancer, on the basis of their unique platform technology and expertise in the field of immune therapy of cancer.